167 related articles for article (PubMed ID: 37115356)
1. In vitro evaluation of (S)-2-amino-3-[3-(2-
Nozaki S; Nakatani Y; Mawatari A; Hume WE; Doi H; Watanabe Y
EJNMMI Res; 2023 Apr; 13(1):36. PubMed ID: 37115356
[TBL] [Abstract][Full Text] [Related]
2. First-in-human assessment of the novel LAT1 targeting PET probe
Nozaki S; Nakatani Y; Mawatari A; Hume WE; Wada Y; Ishii A; Tanaka M; Tsuyuguchi N; Doi H; Watanabe Y
Biochem Biophys Res Commun; 2022 Mar; 596():83-87. PubMed ID: 35121373
[TBL] [Abstract][Full Text] [Related]
3.
Nozaki S; Nakatani Y; Mawatari A; Shibata N; Hume WE; Hayashinaka E; Wada Y; Doi H; Watanabe Y
Sci Rep; 2019 Oct; 9(1):15718. PubMed ID: 31673030
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
5. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
6. Correlation between
Saarinen I; Jambor I; Kim M; Kuisma A; Kemppainen J; Merisaari H; Eskola O; Koskenniemi AR; Perez IM; Boström P; Taimen P; Minn H
EJNMMI Res; 2019 May; 9(1):50. PubMed ID: 31152256
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2.
Okudaira H; Nakanishi T; Oka S; Kobayashi M; Tamagami H; Schuster DM; Goodman MM; Shirakami Y; Tamai I; Kawai K
Nucl Med Biol; 2013 Jul; 40(5):670-5. PubMed ID: 23647854
[TBL] [Abstract][Full Text] [Related]
8. 5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET.
Krämer SD; Mu L; Müller A; Keller C; Kuznetsova OF; Schweinsberg C; Franck D; Müller C; Ross TL; Schibli R; Ametamey SM
J Nucl Med; 2012 Mar; 53(3):434-42. PubMed ID: 22331220
[TBL] [Abstract][Full Text] [Related]
9. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
Toyoda M; Kaira K; Ohshima Y; Ishioka NS; Shino M; Sakakura K; Takayasu Y; Takahashi K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
Br J Cancer; 2014 May; 110(10):2506-13. PubMed ID: 24762957
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FBPA as a tumor specific tracer of L-type amino acid transporter 1 (LAT1): PET evaluation in tumor and inflammation compared to (18)F-FDG and (11)C-methionine.
Watabe T; Hatazawa J
Hell J Nucl Med; 2015; 18 Suppl 1():149. PubMed ID: 26665232
[TBL] [Abstract][Full Text] [Related]
12.
Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
[TBL] [Abstract][Full Text] [Related]
13. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma.
Namikawa M; Kakizaki S; Kaira K; Tojima H; Yamazaki Y; Horiguchi N; Sato K; Oriuchi N; Tominaga H; Sunose Y; Nagamori S; Kanai Y; Oyama T; Takeyoshi I; Yamada M
Hepatol Res; 2015 Sep; 45(9):1014-1022. PubMed ID: 25297701
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [
Nozaki S; Nakatani Y; Mawatari A; Shibata N; Hume WE; Hayashinaka E; Wada Y; Doi H; Watanabe Y
Sci Rep; 2023 Feb; 13(1):1961. PubMed ID: 36737550
[TBL] [Abstract][Full Text] [Related]
15. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Oriuchi N; Nagamori S; Kanai Y
Cancer Sci; 2016 Mar; 107(3):347-52. PubMed ID: 26749017
[TBL] [Abstract][Full Text] [Related]
16. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.
Wongthai P; Hagiwara K; Miyoshi Y; Wiriyasermkul P; Wei L; Ohgaki R; Kato I; Hamase K; Nagamori S; Kanai Y
Cancer Sci; 2015 Mar; 106(3):279-86. PubMed ID: 25580517
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of D-isomer of
Hirai N; Watabe T; Nagamori S; Wiriyasermkul P; Tanaka Y; Romanov V; Naka S; Kanai Y; Liu Y; Tani N; Sakai T; Tatsumi M; Shimosegawa E; Kanai Y; Hatazawa J
Asia Ocean J Nucl Med Biol; 2020; 8(2):102-108. PubMed ID: 32714997
[TBL] [Abstract][Full Text] [Related]
18. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.
Barollo S; Bertazza L; Watutantrige-Fernando S; Censi S; Cavedon E; Galuppini F; Pennelli G; Fassina A; Citton M; Rubin B; Pezzani R; Benna C; Opocher G; Iacobone M; Mian C
PLoS One; 2016; 11(5):e0156044. PubMed ID: 27224648
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
